Researchers published data showing that targeting LRBA triggers degradation of the immune checkpoint CTLA‑4 and enhances anti-tumor immune responses. The Nature Communications study characterizes a mechanism by which LRBA modulation reduces CTLA‑4 levels on T cells, unlocking heightened immune activity against tumors in preclinical models. The finding identifies LRBA as a druggable node to complement existing checkpoint strategies and may inform next-generation immune-modulatory drug programs.